Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MOST-CIRCUIT : Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Female reproductive organs,Sarcoma,Stomach and upper gastrointestinal tractBile duct,Gallbladder,Leiomyosarcoma,Ovary,Pancreas,Stomach,Uterus,Vagina

Trial Overview Read MoreRead more

This phase II trial is trying to determine the clinical benefit of using two types of immunotherapy (nivolumab combined with ipilimumab) to treat neuroendocrine cancers, biliary tract cancers, gynaecological cancers and MSI-H cancers (excluding colorectal cancer).
 

This trial is treating multiple types of cancer including neuroendocrine cancers, biliary tract cancers, gynaecological cancers and MSI-H cancers (excluding colorectal cancer).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers

Commercial Sponsor

Adlai Nortye Biopharma Co., Ltd

Summary

Eligible participants will be treated with Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) concurrently every 3 weeks for 4 doses, followed by nivolumab (480mg) only every 4 weeks until progression (up to 2 years).

Recruiting Hospitals Read MoreRead more

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next